These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

382 related items for PubMed ID: 23962449

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group.
    Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF, Manzione L, Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Myers R, Ianniello GP, Gebbia V, Gasparini G, Fava S, Hirsh V, Bezjak A, Seymour L, Perrone F.
    J Clin Oncol; 2003 Aug 15; 21(16):3025-34. PubMed ID: 12837810
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale.
    Gebbia V, Galetta D, Caruso M, Verderame F, Pezzella G, Valdesi M, Borsellino N, Pandolfo G, Durini E, Rinaldi M, Loizzi M, Gebbia N, Valenza R, Tirrito ML, Varvara F, Colucci G, Gruppo Ocologico Italia Meridionale.
    Lung Cancer; 2003 Feb 15; 39(2):179-89. PubMed ID: 12581571
    [Abstract] [Full Text] [Related]

  • 7. Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG).
    Kotsakis A, Kentepozidis N, Emmanouilidis Ch, Polyzos A, Agelidou A, Vaslamatzis M, Chandrinos V, Agelaki S, Vamvakas L, Kalbakis K, Katsaounis P, Stoltidis D, Nintos G, Hatzidaki D, Vetsika EK, Mavroudis D, Georgoulias V.
    Lung Cancer; 2015 Apr 15; 88(1):57-62. PubMed ID: 25662596
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy.
    Novello S, Kielhorn A, Stynes G, Selvaggi G, De Marinis F, Maestri A, Foggi P, Tilden D, Tonato M, Crinò L, Rinaldi M, Migliorino AM, Scagliotti GV, Italian Lung Cancer Project Investigators.
    Lung Cancer; 2005 Jun 15; 48(3):379-87. PubMed ID: 15893007
    [Abstract] [Full Text] [Related]

  • 10. The cost-effectiveness of four cisplatin-containing chemotherapy regimens in the treatment of stages III B and IV non-small cell lung cancer: an Italian perspective.
    Palmer AJ, Brandt A.
    Monaldi Arch Chest Dis; 1996 Aug 15; 51(4):279-88. PubMed ID: 8909011
    [Abstract] [Full Text] [Related]

  • 11. Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials.
    Pujol JL, Barlesi F, Daurès JP.
    Lung Cancer; 2006 Mar 15; 51(3):335-45. PubMed ID: 16478643
    [Abstract] [Full Text] [Related]

  • 12. Interim analysis of a phase III trial. Triple- vs double-agent chemotherapy for advanced non-small-cell lung cancer. Southern Italy Cooperative Oncology Group.
    Comella P.
    Oncology (Williston Park); 2000 Jul 15; 14(7 Suppl 4):35-40. PubMed ID: 10960944
    [Abstract] [Full Text] [Related]

  • 13. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial.
    Alberola V, Camps C, Provencio M, Isla D, Rosell R, Vadell C, Bover I, Ruiz-Casado A, Azagra P, Jiménez U, González-Larriba JL, Diz P, Cardenal F, Artal A, Carrato A, Morales S, Sanchez JJ, de las Peñas R, Felip E, López-Vivanco G, Spanish Lung Cancer Group.
    J Clin Oncol; 2003 Sep 01; 21(17):3207-13. PubMed ID: 12947054
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer.
    Smith TJ, Hillner BE, Neighbors DM, McSorley PA, Le Chevalier T.
    J Clin Oncol; 1995 Sep 01; 13(9):2166-73. PubMed ID: 7666075
    [Abstract] [Full Text] [Related]

  • 16. [Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in treatment of advanced non-small cell lung cancer (NSCLC)].
    Zhang L, Zhang Y, Li N, Xu F, Pan ZK, Guan ZZ.
    Ai Zheng; 2004 Nov 01; 23(11 Suppl):1455-8. PubMed ID: 15566656
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A randomized phase II trial of sequential gemcitabine plus vinorelbine followed by gemcitabine plus ifosfamide versus gemcitabine plus cisplatin in the treatment of chemo-naive patients with stages III and IV non-small cell lung cancer (NSCLC).
    Grigorescu A, Ciuleanu T, Firoiu E, Muresan DR, Teodorescu G, Basson BR.
    Lung Cancer; 2007 Aug 01; 57(2):168-74. PubMed ID: 17467848
    [Abstract] [Full Text] [Related]

  • 19. A meta-analysis of platinum plus gemcitabine or vinorelbine in the treatment of advanced non-small-cell lung cancer.
    Gao G, Jiang J, Liang X, Zhou X, Huang R, Chu Z, Zhan Q.
    Lung Cancer; 2009 Sep 01; 65(3):339-44. PubMed ID: 19144444
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.